{"denoms":[{"counts":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"123"}],"units":"Participants"}],"groups":[{"description":"Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).","id":"BG000","title":"Lanreotide 120 mg"},{"description":"Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .","id":"BG001","title":"Octreotide 30 mg"},{"description":"Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).","id":"BG002","title":"Octreotide 40 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.02","value":"41.8"},{"groupId":"BG001","spread":"12.89","value":"41.6"},{"groupId":"BG002","spread":"11.63","value":"46.6"},{"groupId":"BG003","spread":"11.60","value":"43.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"62"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"61"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"78"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"11"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}],"title":"Native American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"30"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Full Analysis Set (FAS): comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study."}